1. Scrip
  2. >>New Products

US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia

Attachment Inhibitor Aimed At Heavily Pre-Treated Patients

 
• By Alexandra Shimmings

The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.    

Digital illustration of HIV Virus in Blood Stream in color background
• Source: Shutterstock

The US Food and Drug Administration has approved ViiV Healthcare ’s Rukobia (fostemsavir) for use in HIV patients who are running out of treatment options.

The product is a novel attachment inhibitor that targets the first step of the viral lifecycle to bring a new mechanism of action to the treatment of HIV-1, and one with no pre-existing resistance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.